恩格列净治疗糖尿病肾病的效果及对患者肾功能的影响

The effect of empagliflozin on diabetic kidney disease and its influence on renal function

目的 探析恩格列净治疗糖尿病肾病(DKD)的效果及对患者肾功能的影响。方法 84例DKD患者,根据均衡原则分为对照组和观察组,每组42例。对照组选择胰岛素治疗,观察组在对照组基础上增加恩格列净治疗。对比两组患者血糖水平、收缩压(SBP)、舒张压(DBP)、体重、体质量指数(BMI)、血清炎症指标、血脂水平、不良反应发生情况。结果 治疗后,对照组与观察组糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PBG)、空腹血糖(FBG)水平比较,差异均无统计学意义(P>0.05)。治疗后,观察组DBP、SBP、体重、BMI均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组肿瘤坏死因子-α(TNF-α)、白细胞介素-6水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者尿酸(UA)水平(329.62±40.33)μmol/L、尿白蛋白与肌酐比值(UACR)水平(42.37±4.24)mg/g均低于对照组的(354.00±45.24)μmol/L、(69.05±4.24)mg/g,差异有统计学意义(P<0.05)。治疗后,观察组总胆固醇(TC)水平(3.90±1.29)mmol/L、甘油三酯(TG)水平(1.05±0.33)mmol/L均低于对照组的(4.77±1.20)、(1.20±0.52)mmol/L,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 恩格列净可显著降低DKD患者尿白蛋白水平,改善肾功能,有利于延缓患者疾病进展,具有临床推广应用价值。

Objective To discuss the effect of empagliflozin on diabetic kidney disease(DKD)and its influence on renal function.Methods A total of 84 cases of DKD patients were divided into control group and observation group according to the principle of balance,with 42 cases in each group.The control group was treated with insulin,and the observation group was treated with empagliflozin on the basis of the control group.Patients in both groups were compared in terms of blood glucose level,systolic blood pressure(SBP),diastolic blood pressure(DBP),body weight,body mass index(BMI),serum inflammation indicators,blood lipid levels,and occurrence of adverse reactions.Results After treatment,there was no statistically significant difference in the levels of glycosylated hemoglobin(HbA1c),2 h postprandial blood glucose(2 h PBG),and fasting blood glucose(FBG)between the control group and observation group(P>0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-6 in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the uric acid(UA)level(329.62±40.33)μmol/L and urinary albumin-to-creatinine ratio(UACR)level(42.37±4.24)mg/g of the observation group were lower than(354.00±45.24)μmol/L and(69.05±4.24)mg/g of the control group,and the differences were statistically significant(P<0.05).After treatment,the total cholesterol(TC)level(3.90±1.29)mmol/L and triglyceride(TG)level(1.05±0.33)mmol/L of the observation group were lower than(4.77±1.20)and(1.20±0.52)mmol/L of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Empagliflozin can significantly reduce urinary albumin and improve renal function in DKD patients,which is conducive to delay the progression of disease,and has the value of clinical promotion and application.